ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
36 hedge funds and large institutions have $2.77M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
6% more funds holding
Funds holding: 34 → 36 (+2)
20% less capital invested
Capital invested by funds: $3.48M → $2.77M (-$704K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$12.5K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$10.5K |
| 3 |
Bank of New York Mellon
New York
|
+$6.05K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$5.7K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$2.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.4K |
| 2 |
Renaissance Technologies
New York
|
-$6.24K |
| 3 |
LPL Financial
San Diego,
California
|
-$4K |
| 4 |
CCC
Chelsea Counsel Company
Los Angeles,
California
|
-$514 |
| 5 |
Citigroup
New York
|
-$154 |
IMUC Hedge Fund Activity: Q2 2016 in Review
36 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q2 2016, worth a combined $2.77M — down 20% from $3.48M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IMUC positions and 2 closed out — a net gain of 2 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $12.5K. The largest seller was Citadel Advisors, cutting an estimated $22.4K.
- 36 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q2 2016, up from 34 in Q1 2016.
- Funds reported $2.77M of ImmunoCellular Therapeutics, Ltd. stock for Q2 2016, down 20% quarter-over-quarter.
- 4 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q2 2016 and 2 closed out, a net change of +2 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q2 2016 was Goldman Sachs, an estimated $12.5K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q2 2016 was Citadel Advisors, an estimated $22.4K sold.
Based on aggregated 13F filings for Q2 2016.